Effects of human urinary kallidinogenase in the treatment of acute cere-bral infarction

Objective To evaluate the effects of human urinary kallidinogenase in the treatment of acute cerebral infarction, in order to provide a better way for acute cerebral infarction treatment. Methods 120 patients with acute cerebral infarction from December 2011 to December 2013 in the Central Hospital of Panjin City were selected and divided into two groups, each group had 60 cases. Patients in the control group were given treatment including reasonable selection of mannitol for reducing intracranial pressure, Aspirin for anti-platelet aggregation, prevention of complications,necessary nutritional support, rehabilitation therapy and other conventional treatment. Patients in the treatment group were given urinary kallidinogenase 0.15 PNAu joined in 250 m L of normal saline intravenously once a day for 14 d, on the basis of the control group. The treatment efficacy, neurological deficit score(NIHSS) before and after treatment, live ability after treatment, the recurrence and adverse reactions after treatment were observed in the two groups. Results In the treatment group 17 cases had cured, 31 cases had significant progress, 10 cases had progress, 2 cases had invalid,no one had deteriorate, the total effective rate was 96.67%; while in the control group, there were 12, 21, 8, 16 and 3cases retrospectively, the total effective rate was 68.33%; the difference between the two groups in the total effective rate was statistically significant(P 0.05). After 14 days of treatment, NIHSS score [(7.06±3.64) scores] in the treatment group was significantly lower than that of before treatment [(15.03±5.77) scores] and the control group after treatment [(9.85±4.35) scores], the differences were statistically significant(P 0.05). After treatment activities of daily living score in the treatment group [(58.4±5.6) scores] was significantly higher than that of before treatment [(38.7 ±6.3)scores] and the control group after treatment [(43.3±5.4) scores], the differences were statistically significant(P 0.05).After 14 days of treatment, hs-CRP level [(2.13±0.30) mol/L] in the treatment group was significantly lower than that of before treatment [(6.73 ± 0.78) mol/L] and the control group after treatment [(3.73±0.43) mol/L], the differences were statistically significant(P 0.05). There was no serious adverse reaction. Conclusion Application of human urinary kallidinogenase can significantly improve the functional level of neurological defects in acute ischemic stroke patients,improve living ability of patients in the late life, reduce serum hs-CRP level and inflammatory reaction, which has good clinical curative effect, worthy of clinical application.